AvevoRx Signs Agreement With Takeda To Offer Subcutaneous Immunoglobulin Drug CUVITRU To Patients Under Its Care
Portfolio Pulse from Benzinga Newsdesk
AvevoRx has signed an agreement with Takeda Pharmaceutical Company Limited to offer the subcutaneous immunoglobulin drug CUVITRU to patients under its care. This partnership will allow AvevoRx to provide a critical treatment option to patients with primary immunodeficiency diseases.
September 14, 2023 | 12:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Takeda's partnership with AvevoRx to offer CUVITRU could potentially increase its market share and revenues in the immunoglobulin drug market.
The partnership with AvevoRx allows Takeda to expand the reach of its immunoglobulin drug CUVITRU. This could potentially lead to an increase in sales and revenues for Takeda, positively impacting its stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100